Turpin A, Girard E, Baillet C, Pasquier D, Olivier J, Villers A, et al. Imaging for metastasis in prostate cancer: a review of the literature. Front Oncol. 2020;10:55 https://www.frontiersin.org/article/10.3389/fonc.2020.00055.

Article  PubMed  PubMed Central  Google Scholar 

Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16.

Article  CAS  PubMed  Google Scholar 

Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D, et al. A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients. J Nucl Med. 2021;63:567–72.

Article  PubMed  Google Scholar 

Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, et al. A Phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY). J Urol. 2021 ;206:52–61.

Article  PubMed  PubMed Central  Google Scholar 

Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR Phase III, Multicenter Study. Clin Cancer Res. 2021;27:3674–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE Phase 2 randomized clinical trial. JAMA Oncol. 2020;6:650–9.

Article  PubMed  PubMed Central  Google Scholar 

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter Phase II trial. J Clin Oncol. 2018;36:446–53.

Article  CAS  PubMed  Google Scholar 

Office of the Commissioner. FDA Approves First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer. FDA; 2020. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer.

Center for Drug Evaluation and Research. FDA approves second PSMA-targeted PET imaging drug for men with prostate cancer. FDA; 2021. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer.

Vince RA, Jamieson S, Mahal B, Underwood W. Examining the Racial Disparities in Prostate Cancer. Urology. 2022;163:107–11.

Article  PubMed  Google Scholar 

Chowdhury-Paulino IM, Ericsson C, Vince R, Spratt DE, George DJ, Mucci LA. Racial disparities in prostate cancer among black men: epidemiology and outcomes. Prostate Cancer Prostatic Dis. 2022;25:397–402.

Article  PubMed  Google Scholar 

Jain B, Yamoah K, Lathan CS, Muralidhar V, Mahal BA, Nguyen PL, et al. Racial disparities in treatment delay among younger men with prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:590–2.

Article  PubMed  Google Scholar 

Zavala VA, Bracci PM, Carethers JM, Carvajal-Carmona L, Coggins NB, Cruz-Correa MR, et al. Cancer health disparities in racial/ethnic minorities in the United States. Br J Cancer. 2021;124:315–32.

Article  PubMed  Google Scholar 

Dee EC, Arega MA, Yang DD, Butler SS, Mahal BA, Sanford NN, et al. Disparities in refusal of locoregional treatment for prostate adenocarcinoma. JCO Oncol Pract. 2021;17:e1489–501.

Article  PubMed  PubMed Central  Google Scholar 

Dee EC, Muralidhar V, Arega MA, Kishan AU, Spratt DE, Dess RT, et al. Factors influencing noncompletion of radiation therapy among men with localized prostate cancer. Int J Radiat Oncol*Biol*Phys. 2021;109:1279–85.

Article  PubMed  Google Scholar 

Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77:38–52.

Article  PubMed  Google Scholar 

Waite S, Scott J, Colombo D. Narrowing the gap: imaging disparities in radiology. Radiology 2021;299:27–35.

Article  PubMed  Google Scholar 

Miles RC, Onega T, Lee CI. Addressing potential health disparities in the adoption of advanced breast imaging technologies. Acad Radiol. 2018;25:547–51.

Article  PubMed  PubMed Central  Google Scholar 

Madan RA, Mena E, Lindenberg L, Choyke PL. With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer. J Clin Oncol. 2022;40:3015–9.

Article  PubMed  Google Scholar 

Abraham P, Bishay AE, Farah I, Williams E, Newton IG. Reducing health disparities in radiology through social determinants of health: lessons from the COVID-19 pandemic. Acad Radiol. 2021;28:903–10.

Article  PubMed  Google Scholar 

Dee EC, Pierce LJ, Winkfield KM, Lam MB. In pursuit of equity in cancer care: Moving beyond the Affordable Care Act. Cancer 2022;128:3278–83.

Article  PubMed  Google Scholar 

Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, et al. Association of black race with prostate cancer–specific and other-cause mortality. JAMA Oncol. 2019;5:975–83.

Article  PubMed  PubMed Central  Google Scholar 

Spratt DE, Osborne JR. Disparities in castration-resistant prostate cancer trials. J Clin Oncol. 2015;33:1101–3.

Article  PubMed  PubMed Central  Google Scholar 

Bucknor MD, Lichtensztajn DY, Lin TK, Borno HT, Gomez SL, Hope TA. Disparities in PET imaging for prostate cancer at a tertiary academic medical center. J Nucl Med. 2021;62:695–9.

Article  CAS  PubMed  Google Scholar 

Zhai Z, Zheng Y, Li N, Deng Y, Zhou L, Tian T, et al. Incidence and disease burden of prostate cancer from 1990 to 2017: Results from the Global Burden of Disease Study 2017. Cancer 2020;126:1969–78.

Article  PubMed  Google Scholar 

Czernin J, Adams T, Calais J. More unacceptable denials: now It’s PSMA-targeted PET/CT imaging. J Nucl Med. 2022;63:969–70.

Article  PubMed  Google Scholar 

Taplin SH, Anhang Price R, Edwards HM, Foster MK, Breslau ES, Chollette V, et al. Introduction: Understanding and influencing multilevel factors across the cancer care continuum. JNCI Monogr. 2012;2012:2–10.

Article  Google Scholar 

Shea L, Pesa J, Geonnotti G, Powell V, Kahn C, Peters W. Improving diversity in study participation: Patient perspectives on barriers, racial differences and the role of communities. Health Expect. 2022;25:1979–87.

Article  PubMed  PubMed Central  Google Scholar 

De Las Nueces D, Hacker K, DiGirolamo A, Hicks LS. A systematic review of community-based participatory research to enhance clinical trials in racial and ethnic minority groups. Health Serv Res. 2012;47:1363–86.

Article  PubMed Central  Google Scholar 

Baquet CR, Bromwell JL, Hall MB, Frego JF. Rural community–academic partnership model for community engagement and partnered research. Prog Community Health Partnersh. 2013;7:281–90.

Article  PubMed  PubMed Central  Google Scholar 

Johnson DA, Joosten YA, Wilkins CH, Shibao CA. Case study: community engagement and clinical trial success: outreach to African American women. Clin Transl Sci. 2015;8:388–90.

Article  PubMed  PubMed Central  Google Scholar 

Katz ML, Tatum C, Dickinson SL, Murray DM, Long-Foley K, Cooper MR, et al. Improving colorectal cancer screening by using community volunteers. Cancer 2007;110:1602–10.

Article  PubMed  Google Scholar 

Christy SM, Davis SN, Williams KR, Zhao X, Govindaraju SK, Quinn GP, et al. A community-based trial of educational interventions with fecal immunochemical tests for colorectal cancer screening uptake among blacks in community settings. Cancer 2016;122:3288–96.

Article  PubMed  Google Scholar 

Cole H, Thompson HS, White M, Browne R, Trinh-Shevrin C, Braithwaite S, et al. Community-based, preclinical patient navigation for colorectal cancer screening among older black men recruited from Barbershops: The MISTER B Trial. Am J Public Health. 2017;107:1433–40.

Article  PubMed  PubMed Central  Google Scholar 

Williams LB, Looney SW, Joshua T, McCall A, Tingen MS. Promoting community awareness of lung cancer screening among disparate populations: results of the cancer-community awareness access research and education project. Cancer Nurs. 2021;44:89.

Article  PubMed  Google Scholar 

Menendez R. S.2706 - 117th Congress (2021-2022): DIVERSE Trials Act. 2021. Available from: http://www.congress.gov/.

Unger JM, Hershman DL, Till C, Minasian LM, Osarogiagbon RU, Fleury ME, et al. “When Offered to Participate”: A systematic review and meta-analysis of patient agreement to participate in cancer clinical trials. J Natl Cancer Inst. 2021;113:244–57.

Article  PubMed  Google Scholar 

Institute of Medicine (US) Committee on Routine Patient Care Costs in Clinical Trials for Medicare, Aaron HJ, Gelband H Paying for Patient Care in Clinical Trials. Extending Medicare Reimbursement in Clinical Trials. National Academies Press (US); 2000. Available from: http://www.ncbi.nlm.nih.gov/books/NBK225267/.

Iagaru A, Franc B. Disparities in PET imaging of prostate cancer at a tertiary academic medical center. J Nucl Med. 2021;62:747–8.

Article  PubMed  Google Scholar 

Fact Sheet: White House Announces Initial Steps for Reignited Cancer Moonshot. The White House. Available from: https://www.whitehouse.gov/ostp/news-updates/2022/03/17/fact-sheet-white-house-announces-initial-steps-for-reignited-cancer-moonshot/.

Sultan DH, Gishe J, Hanciles A, Comins MM, Norris CM. Minority use of a National Cancer Institute-Designated Comprehensive Cancer Center and Non-specialty Hospitals in Two Florida regions. J Racial Ethn Health Dispar. 2015;2:373–84.

Article  Google Scholar 

Tikkanen RS, Woolhandler S, Himmelstein DU, Kressin NR, Hanchate A, Lin MY, et al. Hospital payer and racial/ethnic mix at private academic medical centers in Boston and New York City. Int J Health Serv. 2017;47:460–76.

Article